Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Tactile Medical Q1 2026 Earnings Call - Strong Revenue Growth Driven by Lymphedema and Airway Clearance, Raised Full-Year Guidance to $360M-$368M
Tactile Medical delivered a robust Q1 2026, with total revenue rising 23% year-over-year to $75.3 million, propelled by strong performance in both its lymphedema and airway clearance segments. The com...
- Total revenue grew 23% year-over-year to $75.3 million, driven by 23% growth in lymphedema ($62.2M) and 22% growth in airway clearance ($13M).
- Full-year 2026 revenue guidance raised to $360 million-$368 million, reflecting confidence in commercial execution and inclusion of LymphaTech contributions.
- Gross margins expanded 250 basis points to 76.5%, and Adjusted EBITDA reached $3.7 million, up from a $0.3 million loss in Q1 2025, demonstrating strong operating leverage.
- +7 more takeaways
BWX Technologies Q1 2026 Earnings Call - Record Backlog Drives Aggressive U.S. Commercial Expansion
BWX Technologies delivered a strong first quarter, with revenue surging 26% and adjusted EPS climbing 22%, fueled by exceptional operational execution and a record $8.7 billion backlog. The company is...
- Revenue grew 26% year-over-year to $860 million, with 11% organic growth, beating expectations due to improved throughput and favorable work pacing.
- Adjusted EPS rose 22% to $1.12, while adjusted EBITDA increased 14% to $148 million, reflecting strong operational execution across both government and commercial segments.
- Backlog reached a record $8.7 billion, up 77% year-over-year, supported by robust bookings in naval propulsion and accelerating commercial nuclear demand.
- +7 more takeaways
Backblaze First Quarter 2026 Earnings Call - AI-Driven Demand Fuels Revenue Beat and Raised Guidance
Backblaze delivered a strong start to 2026, beating revenue and adjusted EBITDA guidance while accelerating B2 Cloud Storage growth to 24% year-over-year. The quarter was defined by a structural shift...
- Revenue reached $38.7 million, beating the high end of guidance, driven by 24% year-over-year growth in B2 Cloud Storage and stronger-than-expected customer data consumption.
- Adjusted EBITDA jumped to $10 million (26% margin), up from $6 million in the prior year, demonstrating significant operating leverage and cost discipline.
- AI is now a core revenue driver, with over one-third of new bookings originating from AI-related customers and the AI customer base growing 76% year-over-year.
- +9 more takeaways
Inspire Medical Systems Q1 2026 Earnings Call - Coding Chaos and WISeR Delays Cut Full-Year Outlook
Inspire Medical Systems reported a modest 1.6% revenue increase to $204.6 million in Q1 2026, but management immediately pivoted to a revised, lower full-year revenue outlook of $825 million to $875 m...
- Q1 2026 revenue reached $204.6 million, a 1.6% year-over-year increase, driven by higher market penetration and a favorable sales mix of Inspire V systems.
- Management revised full-year 2026 revenue guidance down to $825 million–$875 million, reflecting an estimated $120 million–$150 million in headwinds from coding uncertainty and the WISeR program.
- Q1 revenue was negatively impacted by approximately $20 million due to reimbursement confusion and WISeR delays, with the drag expected to accelerate to $40 million–$50 million in Q2 before improving sequentially.
- +7 more takeaways
Firefly Aerospace Q1 2026 Earnings Call - Record $81M Revenue and Lunar Acceleration
Firefly Aerospace reported a record first quarter 2026, delivering $80.9 million in revenue and expanding its backlog to $1.3 billion, driven by a ramp in defense software and a successful Alpha rocke...
- Record quarterly revenue of $80.9 million surpassed all prior quarters, driven by a full quarter of SciTec defense software and a ramp in the FORGE missile defense program.
- Total backlog stands at approximately $1.3 billion, remaining flat sequentially as the company burned through backlog to generate record revenue.
- Management reiterated its full-year 2026 revenue guidance of $420 million to $450 million, citing strong demand across its spacecraft and launch portfolios.
- +9 more takeaways
Fabrinet Q3 FY2026 Earnings Call - Record Revenue and Earnings Beat Amid Supply Constraints and New Datacom Wins
Fabrinet delivered a record $1.214 billion in revenue for Q3 FY2026, accelerating 39% year-over-year and beating guidance on both top and bottom lines. Non-GAAP EPS hit a record $3.72, driven by stron...
- Revenue hit a record $1.214 billion, up 39% year-over-year and 7% sequentially, exceeding guidance.
- Non-GAAP EPS reached a record $3.72, beating guidance and reflecting strong operating leverage with expenses at 1.4% of revenue.
- Optical Communications revenue grew 35% year-over-year to $889 million, with Telecom surging 55% to a record $628 million.
- +9 more takeaways
Duolingo Q1 2026 Earnings Call - AI Content Velocity and the Monetization Paradox
Duolingo delivered a quarter defined by execution, not just ambition. Daily active users jumped 21% year-over-year as the company doubled down on teaching quality and product stickiness. The real stor...
- DAUs grew 21% year-over-year, meeting management's expectations for the strategic shift toward teaching quality.
- AI-driven content velocity hit a new peak with 20,500 course units published in Q1, a tenfold increase from two years ago.
- Professional proficiency content is now live across the top nine languages, reaching B2 level on the CEFR scale.
- +7 more takeaways
Vertex Pharmaceuticals Q1 2026 Earnings Call - Povi IgAN Data Sparks Renal Franchise Ambitions
Vertex Pharmaceuticals delivered a strong Q1 2026, with revenue rising 8% to $2.99 billion, driven by steady CF growth and early contributions from CASGEVY and JOURNAVX. The company's strategic pivot ...
- Q1 2026 total revenue reached $2.99 billion, an 8% year-over-year increase, with CF revenue growing 6% and new disease areas (CASGEVY and JOURNAVX) contributing approximately 25% of total growth.
- Povi (povetacicept) demonstrated 'sparkling' interim Phase III data in IgAN, achieving a 52% reduction in proteinuria and a 77.4% reduction in serum Gd-IgA1 levels, with a favorable safety profile showing no opportunistic infections.
- Vertex submitted the Biologics License Application (BLA) for Povi in IgAN just 27 days after database lock, marking the fastest regulatory submission in the company's history.
- +7 more takeaways
Allison Transmission Q1 2026 Earnings Call - Synergy Realization Begins as Defense and Mining Drive Growth
Allison Transmission reported a solid first quarter despite macroeconomic headwinds, with Adjusted EBITDA rising 22% year-over-year and adjusted EPS up 6%. The company’s acquisition of Dana Off-Highwa...
- Adjusted EBITDA rose 22% year-over-year to $362 million, with margins holding at 26% despite acquisition-related costs.
- Adjusted diluted EPS increased 6% to $2.57, excluding non-recurring acquisition expenses.
- Defense revenue jumped 64% year-over-year, driven by strong international demand for new transmission programs.
- +7 more takeaways
Advanced Energy Q1 2026 Earnings Call - Margin Breaks 40% as Data Center and Semiconductor Demand Accelerates
Advanced Energy delivered a standout first quarter, with revenue jumping 26% year-over-year to $511 million and gross margin cracking the 40% threshold for the first time since the Artesyn acquisition...
- Revenue surged 26% year-over-year to $511 million, beating the midpoint of guidance, driven by record data center revenue.
- Gross margin exceeded 40% for the first time since the Artesyn acquisition, reflecting improved product mix, manufacturing efficiency, and lower cost of sales.
- Data center computing revenue hit a record $194 million, up 102% year-over-year, with management raising full-year growth expectations to the mid-30% range.
- +7 more takeaways